Breaking News, Financial News

Financial Reports: Alexion

Soliris sales up 44% for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion   4Q Revenues: $599.5 million (+36%) 4Q Earnings: $153.3 million (loss of $19.0 million 4Q13) FY Revenues: $2.2 billion (+44%) FY Earnings: $656.9 million (earnings were $252.9 million FY13) Comments: Soliris sales were $599 million in the quarter, up 36% and to $2.2 billion for the year, up 44%. R&D expenses were up 50% to $129.1 million in the quarter and up 62% to $513.8 million for the year.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters